The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations

Farnad Imani, Mahsa Motavaf, Saeid Safari, Seyed Moayed Alavian, Farnad Imani, Mahsa Motavaf, Saeid Safari, Seyed Moayed Alavian

Abstract

Context: Pain management in cirrhotic patients is a major clinical challenge for medical professionals. Unfortunately there are no concrete guidelines available regarding the administration of analgesics in patients with liver cirrhosis. In this review we aimed to summarize the available literature and suggest appropriate evidence-based recommendations regarding to administration of these drugs.

Evidence acquisition: An indexed MEDLINE search was conducted in July 2014, using keywords "analgesics", "hepatic impairment", "cirrhosis", "acetaminophen or paracetamol", "NSAIDs or nonsteroidal anti-inflammatory drugs", "opioid" for the period of 2004 to 2014. All randomized clinical trials, case series, case report and meta-analysis studies with the above mentioned contents were included in review process. In addition, unpublished information from the Food and Drug Administration are included as well.

Results: Paracetamol is safe in patients with chronic liver disease but a reduced dose of 2-3 g/d is recommended for long-term use. Non-steroidal anti-inflammatory drugs (NSAIDs) are best avoided because of risk of renal impairment, hepatorenal syndrome, and gastrointestinal hemorrhage. Most opioids can have deleterious effects in patients with cirrhosis. They have an increased risk of toxicity and hepatic encephalopathy. They should be administrated with lower and less frequent dosing in these patients and be avoided in patients with a history of encephalopathy or addiction to any substance.

Conclusions: No evidence-based guidelines exist on the use of analgesics in patients with liver disease and cirrhosis. As a result pain management in these patients generates considerable misconception among health care professionals, leading under-treatment of pain in this population. Providing concrete guidelines toward the administration of these agents will lead to more efficient and safer pain management in this setting.

Keywords: Acetaminophen; Adverse Drug Events; Hepatic Cirrhosis; Pain Management.

References

    1. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12(4):733–46. doi: 10.1016/j.cld.2008.07.007. vii.
    1. Graudal N, Leth P, Marbjerg L, Galloe AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991;230(2):165–71.
    1. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403–6.
    1. Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S, et al. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon. 2013;13(8):e23539. doi: 10.5812/hepatmon.11290.
    1. Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, et al. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Saf. 2008;31(3):261–70.
    1. Imani F, Safari S. “Pain Relief is an Essential Human Right”, We Should be Concerned about It. Anesth Pain Med. 2011;1(2):55–7.
    1. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5(2):157–67.
    1. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis. 2002;22(2):123–36. doi: 10.1055/s-2002-30099.
    1. Rahimzadeh P, Safari S, Faiz SH, Alavian SM. Anesthesia for patients with liver disease. Hepat Mon. 2014;14(7) doi: 10.5812/hepatmon.19881.
    1. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61. doi: 10.1007/s00228-008-0553-z.
    1. Safari S, Motavaf M, Seyed Siamdoust SA, Alavian SM. Hepatotoxicity of Halogenated Inhalational Anesthetics. Iran Red Crescent Med J. 2014;16(9) doi: 10.5812/ircmj.20153.
    1. Mohseni M, Safari S, Alavian SM. Volatile anesthetics in ischemic liver injury: enemy or friend? Hepat Mon. 2014;14(6) doi: 10.5812/hepatmon.19880.
    1. Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet. 1979;4(6):423–32.
    1. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529–45.
    1. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology. 1991;13(4):786–95.
    1. Debinski HS, Lee CS, Danks JA, Mackenzie PI, Desmond PV. Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 1995;108(5):1464–9.
    1. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf. 2005;28(3):227–40.
    1. Arnman R, Olsson R. Elimination of paracetamol in chronic liver disease. Acta Hepatogastroenterol (Stuttg). 1978;25(4):283–6.
    1. Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl. 1979;624:99–105.
    1. Alimian M, Pournajafian A, Kholdebarin A, Ghodraty M, Rokhtabnak F, Yazdkhasti P. Analgesic effects of paracetamol and morphine after elective laparotomy surgeries. Anesth Pain Med. 2014;4(2) doi: 10.5812/aapm.12912.
    1. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005;12(2):133–41.
    1. Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study. BMC Med. 2007;5:13. doi: 10.1186/1741-7015-5-13.
    1. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther. 2007;26(2):283–90. doi: 10.1111/j.1365-2036.2007.03368.x.
    1. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F, Spanish Collaborative Study Group on Therapeutic Management of Liver D. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59(1):71–6. doi: 10.1007/s00228-003-0586-2.
    1. Khalid SK, Lane J, Navarro V, Garcia-Tsao G. Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol. 2009;7(9):994–9. doi: 10.1016/j.cgh.2009.04.015.
    1. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93. doi: 10.1001/jama.296.1.87.
    1. American Liver Foundation The American Liver Foundation Issues Warning on Dangers of Excess Acetaminophen. American Liver Foundation. 2006 Available from: .
    1. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451–8. doi: 10.4065/mcp.2009.0534.
    1. Schoene B, Fleischmann RA, Remmer H, von Oldershausen HF. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972;4(2):65–73.
    1. Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, Kelly J, et al. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol. 1984;27(3):291–6.
    1. Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol. 2012;18(24):3035–49. doi: 10.3748/wjg.v18.i24.3035.
    1. Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology. 1993;104(3):869–76.
    1. Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17(6):530–48.
    1. Arroyo V, Gines P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med. 1986;81(2B):104–22.
    1. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330(2):156–60.
    1. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68-69:165–75.
    1. Perez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int. 1984;26(1):72–80.
    1. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563–8.
    1. Peck-Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:21–8. doi: 10.1111/j.1365-2036.2007.03509.x.
    1. De Ledinghen V, Heresbach D, Fourdan O, Bernard P, Liebaert-Bories MP, Nousbaum JB, et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut. 1999;44(2):270–3.
    1. Ackerman Z, Cominelli F, Reynolds TB. Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study. Am J Gastroenterol. 2002;97(8):2033–9. doi: 10.1111/j.1572-0241.2002.05847.x.
    1. Laffi G, Daskalopoulos G, Kronborg I, Hsueh W, Gentilini P, Zipser RD. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology. 1986;90(1):182–7.
    1. Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979;48(6):895–900. doi: 10.1210/jcem-48-6-895.
    1. Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Perez-Ayuso RM, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest. 1983;13(3):271–8.
    1. Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-Del-Arbol L, Gines P, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41(3):579–87. doi: 10.1002/hep.20595.
    1. Brater DC, Anderson SA, Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci. 1987;294(3):168–74.
    1. Bosch-Marce M, Claria J, Titos E, Masferrer JL, Altuna R, Poo JL, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology. 1999;116(5):1167–75.
    1. Lopez-Parra M, Claria J, Planaguma A, Titos E, Masferrer JL, Woerner BM, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol. 2002;135(4):891–900. doi: 10.1038/sj.bjp.0704528.
    1. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S37–42.
    1. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289–97.
    1. Hajiesmaeili MR, Safari S. Pain management in the intensive care unit: do we need special protocols? Anesth Pain Med. 2012;1(4):237–8. doi: 10.5812/aapm.4523.
    1. Eydi M, Golzari SE, Aghamohammadi D, Kolahdouzan K, Safari S, Ostadi Z. Postoperative Management of Shivering: A Comparison of Pethidine vs. Ketamine. Anesth Pain Med. 2014;4(2) doi: 10.5812/aapm.15499.
    1. Imani F, Faiz HR, Sedaghat M, Hajiashrafi M. Effects of adding ketamine to fentanyl plus acetaminophen on postoperative pain by patient controlled analgesia in abdominal surgery. Anesth Pain Med. 2014;4(1) doi: 10.5812/aapm.12162.
    1. Durnin C, Hind ID, Ghani SP, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc. 2001;44:83–4.
    1. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther. 1997;61(6):655–61. doi: 10.1016/S0009-9236(97)90100-4.
    1. Moradi M, Esmaeili S, Shoar S, Safari S. Use of oxycodone in pain management. Anesth Pain Med. 2012;1(4):262–4. doi: 10.5812/aapm.4529.
    1. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–24. doi: 10.1016/S0025-6196(11)60750-7.
    1. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60(22):1953–64.
    1. Franz CC, Egger S, Born C, Ratz Bravo AE, Krahenbuhl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012;68(2):179–88. doi: 10.1007/s00228-011-1105-5.
    1. Lee YC, Chang CH, Lin JW, Chen HC, Lin MS, Lai MS. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int. 2012;32(5):859–66. doi: 10.1111/j.1478-3231.2011.02739.x.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel